Kamada Ltd. Enters into Two New Agreements for the Distribution of Three Biosimilar Products in Israel
January 13, 2021 at 05:30 pm IST
Kamada Ltd. announced that the Company has entered into agreements with two undisclosed international pharmaceutical companies to commercialize three biosimilar product candidates in Israel. Subject to approval by the European Medicines Agency (EMA) and subsequently by the Israeli Ministry of Health (IMOH), the three products are expected to be launched in Israel between 2022 and 2024. The two pharmaceutical companies will maintain development, manufacturing, and supply responsibilities for these three products.